These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: The North American experience with the Ablate and Pace Trial (APT) for medically refractory atrial fibrillation.
    Author: Wood MA, Kay GN, Ellenbogen KA.
    Journal: Europace; 1999 Jan; 1(1):22-5. PubMed ID: 11220534.
    Abstract:
    The Ablate and Pace Trial (APT) was a prospective registry study of clinical outcomes and survival following ablation and pacing therapy for medically refractory atrial fibrillation. One hundred and fifty-six patients were enrolled at 16 centres in North America. The mean patient age was 66 +/- 11 years, with mean left ventricular ejection fraction of 48% +/- 18%. Seventy-eight percent of the patients had structural heart disease. During one year of follow up, multiple measures of quality-of-life showed significant and sustained improvement following ablation and pacing therapy. Also, left ventricular ejection increased significantly for patients with baseline left ventricular ejection fraction <45%. Metabolic exercise testing showed trends toward improved exercise tolerance; however, these did not achieve statistical significance. The one year overall survival was 85%, with 3% of patients experiencing sudden death. In summary, this large, non-randomized, trial showed significant improvement in quality of life and left ventricular function following ablation and pacing therapy. Ablation and pacing therapy is a viable strategy for palliative management of patients with medically refractory, highly symptomatic atrial fibrillation.
    [Abstract] [Full Text] [Related] [New Search]